170 related articles for article (PubMed ID: 24604381)
1. Comparative nonclinical assessments of the proposed biosimilar PF-05280586 and rituximab (MabThera®).
Ryan AM; Sokolowski SA; Ng CK; Shirai N; Collinge M; Shen AC; Arrington J; Radi Z; Cummings TR; Ploch SA; Stephenson SA; Tripathi NK; Hurst SI; Finch GL; Leach MW
Toxicol Pathol; 2014 Oct; 42(7):1069-81. PubMed ID: 24604381
[TBL] [Abstract][Full Text] [Related]
2. A phase I pharmacokinetics trial comparing PF-05280586 (a potential biosimilar) and rituximab in patients with active rheumatoid arthritis.
Cohen S; Emery P; Greenwald M; Yin D; Becker JC; Melia LA; Li R; Gumbiner B; Thomas D; Spencer-Green G; Meng X
Br J Clin Pharmacol; 2016 Jul; 82(1):129-38. PubMed ID: 26909489
[TBL] [Abstract][Full Text] [Related]
3. A Randomized, Double-Blind, Efficacy and Safety Study of PF-05280586 (a Rituximab Biosimilar) Compared with Rituximab Reference Product (MabThera
Sharman JP; Liberati AM; Ishizawa K; Khan T; Robbins J; Alcasid A; Rosenberg JA; Aurer I
BioDrugs; 2020 Apr; 34(2):171-181. PubMed ID: 31820339
[TBL] [Abstract][Full Text] [Related]
4. Subcutaneous versus intravenous administration of rituximab: pharmacokinetics, CD20 target coverage and B-cell depletion in cynomolgus monkeys.
Mao CP; Brovarney MR; Dabbagh K; Birnböck HF; Richter WF; Del Nagro CJ
PLoS One; 2013; 8(11):e80533. PubMed ID: 24265828
[TBL] [Abstract][Full Text] [Related]
5. Developmental immunotoxicology assessment of rituximab in cynomolgus monkeys.
Vaidyanathan A; McKeever K; Anand B; Eppler S; Weinbauer GF; Beyer JC
Toxicol Sci; 2011 Jan; 119(1):116-25. PubMed ID: 20937725
[TBL] [Abstract][Full Text] [Related]
6. Nonclinical assessments of the potential biosimilar PF-06439535 and bevacizumab.
Peraza MA; Rule KE; Shiue MHI; Finch GL; Thibault S; Brown PR; Clarke DW; Leach MW
Regul Toxicol Pharmacol; 2018 Jun; 95():236-243. PubMed ID: 29574193
[TBL] [Abstract][Full Text] [Related]
7. Comparative nonclinical assessments of the proposed biosimilar PF-05280014 and trastuzumab (Herceptin(®)).
Hurst S; Ryan AM; Ng CK; McNally JM; Lorello LG; Finch GL; Leach MW; Ploch SA; Fohey JA; Smolarek TA
BioDrugs; 2014 Oct; 28(5):451-9. PubMed ID: 25001079
[TBL] [Abstract][Full Text] [Related]
8. Nonclinical Evaluation of PF-06438179: A Potential Biosimilar to Remicade
Derzi M; Johnson TR; Shoieb AM; Conlon HD; Sharpe P; Saati A; Koob S; Bolt MW; Lorello LG; McNally J; Kirchhoff CF; Smolarek TA; Leach MW
Adv Ther; 2016 Nov; 33(11):1964-1982. PubMed ID: 27585978
[TBL] [Abstract][Full Text] [Related]
9. Factors Influencing Infusion-Related Reactions Following Dosing of Reference Rituximab and PF-05280586, a Rituximab Biosimilar.
Courville J; Nastoupil L; Kaila N; Kelton J; Zhang J; Alcasid A; Nava-Parada P
BioDrugs; 2021 Jul; 35(4):459-468. PubMed ID: 34152584
[TBL] [Abstract][Full Text] [Related]
10. Biosimilar monoclonal antibodies in lymphoma: a critical appraisal.
Rioufol C; Salles G
Expert Rev Anticancer Ther; 2015 May; 15(5):569-78. PubMed ID: 25818308
[TBL] [Abstract][Full Text] [Related]
11. Comparative nonclinical assessments of the biosimilar PF-06410293 and originator adalimumab.
Derzi M; Shoieb AM; Ripp SL; Finch GL; Lorello LG; O'Neil SP; Radi Z; Syed J; Thompson MS; Leach MW
Regul Toxicol Pharmacol; 2020 Apr; 112():104587. PubMed ID: 32006671
[TBL] [Abstract][Full Text] [Related]
12. Comparability of Antibody-Mediated Cell Killing Activity Between a Proposed Biosimilar RTXM83 and the Originator Rituximab.
Cuello HA; Segatori VI; Alberto M; Pesce A; Alonso DF; Gabri MR
BioDrugs; 2016 Jun; 30(3):225-31. PubMed ID: 27053342
[TBL] [Abstract][Full Text] [Related]
13. Differential in vivo effects of rituximab on two B-cell subsets in cynomolgus monkeys.
Vugmeyster Y; Howell K; McKeever K; Combs D; Canova-Davis E
Int Immunopharmacol; 2003 Oct; 3(10-11):1477-81. PubMed ID: 12946444
[TBL] [Abstract][Full Text] [Related]
14. Extension Study of PF-05280586, a Potential Rituximab Biosimilar, Versus Rituximab in Subjects With Active Rheumatoid Arthritis.
Cohen SB; Burgos-Vargas R; Emery P; Jin B; Cronenberger C; Vázquez-Abad MD
Arthritis Care Res (Hoboken); 2018 Nov; 70(11):1598-1606. PubMed ID: 29692005
[TBL] [Abstract][Full Text] [Related]
15. Rituximab-mediated depletion of cynomolgus monkey B cells in vitro in different matrices: possible inhibitory effect of IgG.
Vugmeyster Y; Howell K
Int Immunopharmacol; 2004 Aug; 4(8):1117-24. PubMed ID: 15222987
[TBL] [Abstract][Full Text] [Related]
16. Effect of anti-CD20 monoclonal antibody, Rituxan, on cynomolgus monkey and human B cells in a whole blood matrix.
Vugmeyster Y; Howell K; Bakshl A; Flores C; Canova-Davis E
Cytometry A; 2003 Apr; 52(2):101-9. PubMed ID: 12655653
[TBL] [Abstract][Full Text] [Related]
17. A phase I pharmacokinetics study comparing PF-06439535 (a potential biosimilar) with bevacizumab in healthy male volunteers.
Knight B; Rassam D; Liao S; Ewesuedo R
Cancer Chemother Pharmacol; 2016 Apr; 77(4):839-46. PubMed ID: 26984210
[TBL] [Abstract][Full Text] [Related]
18. Low-dose rituximab is effective in pemphigus.
Horváth B; Huizinga J; Pas HH; Mulder AB; Jonkman MF
Br J Dermatol; 2012 Feb; 166(2):405-12. PubMed ID: 21967609
[TBL] [Abstract][Full Text] [Related]
19. An afucosylated anti-CD20 monoclonal antibody with greater antibody-dependent cellular cytotoxicity and B-cell depletion and lower complement-dependent cytotoxicity than rituximab.
Gasdaska JR; Sherwood S; Regan JT; Dickey LF
Mol Immunol; 2012 Mar; 50(3):134-41. PubMed ID: 22305040
[TBL] [Abstract][Full Text] [Related]
20. PKPD Assessment of the Anti-CD20 Antibody Obinutuzumab in Cynomolgus Monkey is Feasible Despite Marked Anti-Drug Antibody Response in This Species.
Grimm HP; Schick E; Hainzl D; Justies N; Yu L; Klein C; Husar E; Richter WF
J Pharm Sci; 2019 Nov; 108(11):3729-3736. PubMed ID: 31351865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
